Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH17 biparatopic antibody drug conjugate
- Development stage
- Preclinical
- Lead developer
- NovaRock Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The CDH17 biparatopic antibody drug conjugate is an investigational biologic being developed by NovaRock Biotherapeutics for the treatment of gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers. It utilizes a biparatopic antibody format designed to target two distinct epitopes on Cadherin-17 (CDH17), a cell-surface protein highly expressed in the gastrointestinal tract's malignant tissues but restricted in normal tissues. This dual-epitope targeting is intended to enhance internalization and the delivery of a cytotoxic payload directly to tumor cells. As of 2024, the program is in the IND-enabling stage of development.
- Other names
- CDH17 biparatopic ADCCDH-17 biparatopic ADCCDH 17 biparatopic ADCCDH17 biparatopic ADC antibodyCDH-17 biparatopic ADC antibodyCDH 17 biparatopic ADC antibody
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CDH17 biparatopic antibody drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH17 biparatopic antibody drug conjugate.